Focused On-demand Library for Serine/threonine-protein kinase 32A

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q8WU08

UPID:
ST32A_HUMAN

ALTERNATIVE NAMES:
Yet another novel kinase 1

ALTERNATIVE UPACC:
Q8WU08; B3KSY0

BACKGROUND:
The protein known as Serine/threonine-protein kinase 32A, with its alternative name Yet another novel kinase 1, is a pivotal component of the cellular signaling machinery. It is responsible for the phosphorylation of serine and threonine, crucial steps in the modulation of cellular functions. The comprehensive understanding of its role and mechanisms is still under investigation, positioning it as a focal point for ongoing research.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Serine/threonine-protein kinase 32A unveils new horizons for the development of innovative therapeutic approaches. Given its central role in phosphorylation, it holds promise as a novel target in the realm of drug development, offering opportunities to tackle diseases at their molecular roots.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8682 of 8789